Malignant tumor which that arises from uncontrolled proliferation of melanocytes is melanoma. Its rare in India, compared to other tropical countries. Fair skin populations have higher incidences The relative mortality reduced nearly half with scrupulous use sunscreens - SPF 50 blocks 98% UVB rays. Melanomas are observed more countries like Australia and New Zealand (due actinic rays (UV B rays...

Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase ...

The approval of ipilimumab1 and, subsequently, the braf inhibitors vemurafenib2 and dabrafenib3 for the treatment of metastatic melanoma has improved survival in this hitherto often fatal disease. However, resistance to those agents limits efficacy. The keynote-001 phase i study evaluated the use of pembrolizumab, an anti–PD-1 antibody in metastatic melanoma, in treatment-naïve and refractory d...

PURPOSE Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. PATIENTS AND METHODS Patients were all treated with Vemurafenib 960 m...

INTRODUCTION The present study aimed to inform an economic evaluation of dabrafenib and trametinib combination as first-line treatment of metastatic melanoma in a Canadian setting. A network meta-analysis was conducted to estimate hazard ratios (HRs) for progression-free survival (PFS)and overall survival (OS) of dabrafenib plus trametinib versus other first-line treatments of BRAF mutation-pos...

The incorporation of individualized molecular therapeutics into routine clinical practice for both non-small cell lung cancer (NSCLC) and melanoma are amongst the most significant advances of the last decades in medical oncology. In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive...